Literature DB >> 1780988

Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire.

U Bronner1, F Doua, O Ericsson, L L Gustafsson, T W Miézan, M Rais, L Rombo.   

Abstract

Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid (CSF) were determined in 11 patients with Trypanosoma gambiense infection without involvement of the central nervous system in Côte d'Ivoire. Blood samples were drawn during a 48 h period after the first and last dose of pentamidine dimesylate given as 10 intramuscular injections on alternate days. Maximum plasma concentrations were generally attained within one hour after injection but varied extensively (420-13420 nmol/litre). The median plasma concentration 48 h after the last dose was approximately 5 times higher than that after the first dose. The ratio between whole blood and plasma concentration was approximately 2. Small amounts of the drug were found in the CSF after the last dose. The findings showed inter-individual differences in the pharmacokinetics of pentamidine. The currently recommended daily dose regimen could be questioned, as drug accumulation was pronounced. All patients were cured and the concentrations attained should be considered as parasiticidal. Further studies on the kinetics and distribution after single and multiple doses of pentamidine as well as studies on the possible relationship between adverse effects and plasma concentrations are, however, needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1780988     DOI: 10.1016/0035-9203(91)90364-5

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  17 in total

Review 1.  Tropical medicine.

Authors:  H W Murray; J Pépin; T B Nutman; S L Hoffman; A A Mahmoud
Journal:  BMJ       Date:  2000-02-19

2.  Pentamidine inhibits Coxiella burnetii growth and 23S rRNA intron splicing in vitro.

Authors:  Michael F Minnick; Linda D Hicks; James M Battisti; Rahul Raghavan
Journal:  Int J Antimicrob Agents       Date:  2010-10       Impact factor: 5.283

3.  In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.

Authors:  Marcel Kaiser; Michael A Bray; Monica Cal; Bernadette Bourdin Trunz; Els Torreele; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

5.  Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.

Authors:  U Bronner; L L Gustafsson; F Doua; O Ericsson; T Miézan; M Rais; L Rombo
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

6.  The effect of pentamidine on melanoma ex vivo.

Authors:  Jason Smith; Benjamin J Stewart; Sharon Glaysher; Katharine Peregrin; Louise A Knight; David J Weber; Ian A Cree
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

Review 7.  Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.

Authors:  Andrew Jonathan Nok
Journal:  Parasitol Res       Date:  2003-01-31       Impact factor: 2.289

8.  Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Harry Pieter De Koning; Sarah Ann Thomas
Journal:  J Pharmacol Exp Ther       Date:  2009-03-04       Impact factor: 4.030

Review 9.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

10.  Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program.

Authors:  Olaf Valverde Mordt; Antoine Tarral; Nathalie Strub-Wourgaft
Journal:  Am J Trop Med Hyg       Date:  2022-03-15       Impact factor: 3.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.